antiviral medicine remdesivir from Gilead Sciences failed to speed the improvement of patients with Covid-19 or prevent them from dying, according to results from a long-awaited clinical trial conducted in China. Gilead, however, said the data suggest a “potential benefit.”A summary of the study results was inadvertently posted to the website of the World Health Organization and seen by STAT on Thursday, but then removed.
“A draft document was provided by the authors to WHO and inadvertently posted on the website and taken down as soon as the mistake was noticed. The manuscript is undergoing peer review and we are waiting for a final version before WHO comments,” said WHO spokesperson Tarik Jasarevic.
Gilead spokesperson Amy Flood said the company believes “the post included inappropriate characterization of the study.” Because the study was stopped early because it had too few patients, she said, it cannot “enable statistically meaningful conclusions.” However, she said, “trends in the data suggest a potential benefit for remdesivir, particularly among patients treated early in disease.”
The data will be closely scrutinized but are also likely imperfect. The study was terminated prematurely, which could have affected the results. The context that would be provided by a full manuscript is missing, and the data have not been reviewed as normally occurs before publication.
Data on Gilead’s remdesivir show NO benefit for coronavirus！刚刚股市直接跳水，找了半天是这个原因。。。。。 https://www.statnews.com/2020/04/23/data-on-gileads-remdesivir-released-by-accident-show-no-benefit-for-coronavirus-patients/ antiviral medicine remdesivir from Gilead Sciences failed to speed the improvement of patients with Covid-19 or prevent them from dying, according to results from a long-awaited clinical trial conducted in China. Gilead, however, said the data suggest a “potential benefit.”A summary of the study results was inadvertently posted to the website of the World Health Organization and seen by STAT on Thursday, but then removed. “A draft document was provided by the authors to WHO and inadvertently posted on the website and taken down as soon as the mistake was noticed. The manuscript is undergoing peer review and we are waiting for a final version before WHO comments,” said WHO spokesperson Tarik Jasarevic. Gilead spokesperson Amy Flood said the company believes “the post included inappropriate characterization of the study.” Because the study was stopped early because it had too few patients, she said, it cannot “enable statistically meaningful conclusions.” However, she said, “trends in the data suggest a potential benefit for remdesivir, particularly among patients treated early in disease.” The data will be closely scrutinized but are also likely imperfect. The study was terminated prematurely, which could have affected the results. The context that would be provided by a full manuscript is missing, and the data have not been reviewed as normally occurs before publication. layjohns 发表于 4/23/2020 12:57:00 PM
antiviral medicine remdesivir from Gilead Sciences failed to speed the improvement of patients with Covid-19 or prevent them from dying, according to results from a long-awaited clinical trial conducted in China. Gilead, however, said the data suggest a “potential benefit.”A summary of the study results was inadvertently posted to the website of the World Health Organization and seen by STAT on Thursday, but then removed.
“A draft document was provided by the authors to WHO and inadvertently posted on the website and taken down as soon as the mistake was noticed. The manuscript is undergoing peer review and we are waiting for a final version before WHO comments,” said WHO spokesperson Tarik Jasarevic.
Gilead spokesperson Amy Flood said the company believes “the post included inappropriate characterization of the study.” Because the study was stopped early because it had too few patients, she said, it cannot “enable statistically meaningful conclusions.” However, she said, “trends in the data suggest a potential benefit for remdesivir, particularly among patients treated early in disease.”
The data will be closely scrutinized but are also likely imperfect. The study was terminated prematurely, which could have affected the results. The context that would be provided by a full manuscript is missing, and the data have not been reviewed as normally occurs before publication.
Data on Gilead’s remdesivir show NO benefit for coronavirus！刚刚股市直接跳水，找了半天是这个原因。。。。。 https://www.statnews.com/2020/04/23/data-on-gileads-remdesivir-released-by-accident-show-no-benefit-for-coronavirus-patients/ antiviral medicine remdesivir from Gilead Sciences failed to speed the improvement of patients with Covid-19 or prevent them from dying, according to results from a long-awaited clinical trial conducted in China. Gilead, however, said the data suggest a “potential benefit.”A summary of the study results was inadvertently posted to the website of the World Health Organization and seen by STAT on Thursday, but then removed. “A draft document was provided by the authors to WHO and inadvertently posted on the website and taken down as soon as the mistake was noticed. The manuscript is undergoing peer review and we are waiting for a final version before WHO comments,” said WHO spokesperson Tarik Jasarevic. Gilead spokesperson Amy Flood said the company believes “the post included inappropriate characterization of the study.” Because the study was stopped early because it had too few patients, she said, it cannot “enable statistically meaningful conclusions.” However, she said, “trends in the data suggest a potential benefit for remdesivir, particularly among patients treated early in disease.” The data will be closely scrutinized but are also likely imperfect. The study was terminated prematurely, which could have affected the results. The context that would be provided by a full manuscript is missing, and the data have not been reviewed as normally occurs before publication. layjohns 发表于 4/23/2020 12:57:00 PM
Jefferies remdesivir Rem-D Mixed data? Probably some benefit but modest Key points: (1) This is disappointing to not show at least positive trends on efficacy or safety, so expectations will come down now for the GILD-sponsored studies coming up (severe patients with no placebo arm due in next week, and moderate patients with a control arm (standard care but no RemD) due by end of May. The one tidbit that isn't positive too is there appeared to be no big viral reduction (stopping the virus) or virologic benefit in drug patients (which is how the drug is supposed to work and would support biological rationale for why it's helping pts scientifically). However, this may not be shocking in severe patients who are too far gone. Either way, expectations were probably far too elevated after a 10-15% move last week on other media reports from University of Chicago. (2) However, the study was halted early and was not well-powered so bulls will say the study is flawed. In addition, GILD has suggested the study not only was never completed by the China govt, but there may be positive trends in "healthier" pts or those who were treated earliest, which makes logical sense and may be good support for the upcoming moderate patients study later in May which is against a placebo. Of note, China also stopped their moderate study too, so both studies in China were stopped early.
https://www.statnews.com/2020/04/23/data-on-gileads-remdesivir-released-by-accident-show-no-benefit-for-coronavirus-patients/
antiviral medicine remdesivir from Gilead Sciences failed to speed the improvement of patients with Covid-19 or prevent them from dying, according to results from a long-awaited clinical trial conducted in China. Gilead, however, said the data suggest a “potential benefit.”A summary of the study results was inadvertently posted to the website of the World Health Organization and seen by STAT on Thursday, but then removed.
“A draft document was provided by the authors to WHO and inadvertently posted on the website and taken down as soon as the mistake was noticed. The manuscript is undergoing peer review and we are waiting for a final version before WHO comments,” said WHO spokesperson Tarik Jasarevic.
Gilead spokesperson Amy Flood said the company believes “the post included inappropriate characterization of the study.” Because the study was stopped early because it had too few patients, she said, it cannot “enable statistically meaningful conclusions.” However, she said, “trends in the data suggest a potential benefit for remdesivir, particularly among patients treated early in disease.”
The data will be closely scrutinized but are also likely imperfect. The study was terminated prematurely, which could have affected the results. The context that would be provided by a full manuscript is missing, and the data have not been reviewed as normally occurs before publication.
不发布数据你们说赖着不给，发了数据有问题吗？
不是说病人不够吗？
没公信度的社会，你想要外人怎么看。
公信度的积累是很难的，平时中国不在乎，现在想让人家相信，又怪人家不相信
官方发的就当瞎扯好了，等其他国家实验的消息
$30 million 更有用。
等其他结果吧，中国推药都是有政治目的，比如推中药，啥实验也没有就可以直接说中药有效
既然没用，还抢占专利，去“援助”意大利还带着这个山寨药，还帮别的国家生产这个药，现在跳出来说没用？中国的数据，永远都是为政治服务。
中国不是今天promise给钱吗？哈哈
你牛逼，嘴一张什么敢说。
没问题啊，就像0.33一样，这种数据还是留着自己玩吧，玩完了再来一杯双黄连加莲花轻吻，爽死了
先不说别的，就算这些数据是真的，分析是没有偏差的。中国的trial可是早早就提前终止了，说没有足够的病人。
病人不够的情况下显示不出有效性这事很奇怪吗？更不要说很有可能的数据污染，不合条件的病人入组等等。
没有peer review，然后WHO还不小心泄露了又秒删，这是学娱乐圈明星炒绯闻吗？
WHO真牛，各种骚操作
Wow, 真是开眼。祝你一辈子都不要被骗，你全家人也不要被骗。
Ccp and who视人命为儿戏，狼狈为奸，必将遭国际公审。
我们俩真聪明。同哈哈哈。
中药中医就是有意故意的骗子。
你是mit那个niuheliang本尊吗？
"long-awaited clinical trial conducted in China" ==> 表示这个报道可信度基本为0。
说到底就是莲花清瘟牛。不用管病毒，只管细胞不发炎，人不死。
限制条件太多，还不一定对所有病人有效，更多trial结果出来也不一定有确切结论
完全同意
特别是如果Rem在美国临床试验被最终证明有效，这次“消息泄露”会使WHO名誉尽失
对，还是世界第一个做出来的哦。这前方台子都搭好了，就等后面唱戏的上场了
早就脸都掉光了，哪来的名誉
这不至于吧
难混的是中国，不是中国人。其它行业被中国坑过的不少了，Gilead就是太傻白甜。
说反了吧，带方向这么带可不成，要打擦边球，慢慢带，你这一下就暴露了
美国太官僚，口罩都不让戴，何况是直接打人身体里的药。
似乎用处不大。我认识的一个人在重症的时候用了这个药，算是同情用药，还是没救过来。
赶紧买它的股票啊，别光说不做。
你就祈祷最好你不要有用到这药的一天
难道不应该是先签字，不管病得多厉害坚决不用这个药？
看了半天，就这个回答还算是就事论事的讨论。
其他的，都是事先有了结论，不符合结论的，就是假的，就是犯罪，都先骂了再说。
如果说，只有说这药有效才是事实，才是真理，否则就是与全人类为敌。那还搞双盲干嘛？
干脆把这药归为肺炎一号一个档次不就行了嘛，信则灵，不信则不灵。
应该不是出了个无效的报告，而是目前根本没有报告。
按照入双盲人数不足的说法，这个实验无法得出药物是有效还是无效的结论。
还有莲花清瘟